 |
PDF »
March 23, 2006
Cougar Biotechnology to Present at SoCalBio Investor Conference
Los Angeles, CA, March 23, 2006 - Cougar Biotechnology, Inc, a privately held biotechnology company, today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the 8th SoCalBio Investor Conference that will take place on March 29th-30th at the Wilshire Grand Hotel in downtown Los Angeles. This conference is organized by the Southern California Biomedical Council as a forum for facilitating the interaction between life-science entrepreneurs, investors, other members of the financial community, and senior representatives from the healthcare industry.
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in a Phase I clinical trial in prostate cancer, CB3304, which is currently in a Phase I trial in non-Hodgkin’s lymphoma and CB1089, which has been clinically tested in a number of solid tumor types.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
Contact
Alan H. Auerbach
Cougar Biotechnology, Inc.
+1 310 443 4209
ahauerbach@cougarbiotechnology.com
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
